The FDA approved Merus' new cancer drug, Bizengri, for treating advanced pancreatic and lung cancers.

The U.S. FDA has granted accelerated approval to Merus' new drug, Bizengri, for treating advanced NRG1-positive cancers in the pancreas and lungs. Approved for pancreatic adenocarcinoma and non-small cell lung cancer, the drug's approval is based on preliminary data from the eNRGy trial, with ongoing studies to confirm its efficacy. This marks the first FDA approval for Merus' Biclonics technology.

December 04, 2024
7 Articles

Further Reading